Catalysts
FPA144 + chemo Phase 3 futility analysis due 1H 2020
FPA150 Phase 1b Ovarian cancer data due 1H 2020
Cabiralizumab (FPA008) and Opdivo (nivolumab) Phase 2 Data due 2H 2020
- High hedge fund buying in December -
BVF Partners holds a 10% ownership, Frpx Ranks 22 in their portfolio
RENAISSANCE TECHNOLOGIES holds a 3.6% stake in the company
FPA144 + chemo Phase 3 futility analysis due 1H 2020
FPA150 Phase 1b Ovarian cancer data due 1H 2020
Cabiralizumab (FPA008) and Opdivo (nivolumab) Phase 2 Data due 2H 2020
- High hedge fund buying in December -
BVF Partners holds a 10% ownership, Frpx Ranks 22 in their portfolio
RENAISSANCE TECHNOLOGIES holds a 3.6% stake in the company